AroCell AB (Nasdaq First North Growth Market:AROC), a Swedish supplier of blood and urine sample tests, announced on Friday that it has received patent approval in China for its invention on detecting and classifying respiratory infections.
This follows earlier approvals from the European Patent Office in July 2024 and the Japanese Patent Office in September 2024.
The patent covers the use of serum thymidine kinase 1 (STK1) to diagnose Mycoplasma pneumonia and classify respiratory infections as bacterial, viral or caused by M. pneumoniae. Chinese approval strengthens AroCell's intellectual property portfolio across key global markets.
While AroCell primarily focuses on urology, the patent supports the potential clinical application of its TK 210 ELISA technology in respiratory infections. The company now has expanded opportunities for its diagnostic solutions in China, the EU and Japan.
Roivant to announce Q3 2026 financial results
Avacta secures FDA clearance for second pre|CISION oncology programme
OncoHost receives BIG Innovation Award in Health category
Summit Therapeutics and GSK form collaboration to study ivonescimab combination therapy
Summit Therapeutics submits FDA application for ivonescimab in EGFR-mutated lung cancer
Antin to acquire clinical trial equipment provider Emsere
Merck completes acquisition of Cidara Therapeutics for USD9.2bn
Bambusa Therapeutics reports first patient dosed in proof-of-concept COPD trial
Kelun-Biotech lung cancer drug granted Breakthrough Therapy Designation in China
INOVIO's INO-3107 Biologics License Application accepted by US FDA
Sanofi and Regeneron's Dupixent gains Japan approval for paediatric asthma patients aged 6 to 11
Aqualung Therapeutics' Phase 2a lung fibrosis study approved by US FDA